Rotigotine

Publisher Website
Google Scholar
Abstract
▲ Rotigotine is a nonergolinic dopamine D3/D2/D1 receptor agonist delivered via a transdermal system and has been evaluated for the treatment of idiopathic Parkinson’s disease. ▲ Patients with early Parkinson’s disease receiving rotigotine monotherapy experienced significantly greater improvements in parkinsonian symptoms (as measured by Unified Parkinson’s Disease Rating Scale scores) compared to placebo in two large, well designed clinical trials. Significant beneficial effects versus placebo were observed with the 30 and 40 cm2 rotigotine patches in both trials. ▲ Patients with advanced Parkinson’s disease receiving rotigotine as adjunctive therapy with levodopa experienced clinically significant reductions from baseline in ‘off’ time in two well designed clinical trials. In one trial, a large placebo effect was observed, therefore, there was no significant difference between placebo and active treatment (20, 40 and 60 cm2) for this primary efficacy variable, However, a recent study found a significant (p ≤ 0.003) reduction in ‘off’ time in rotigotine 40 and 60 cm2 recipients versus that in the placebo group. ▲ Rotigotine was generally well tolerated in clinical trials as both monotherapy and when administered with levodopa; adverse events were generally mild or moderate in severity.